CTSS and Stroke: Assuming there is no difference in the rate at which these two molecules have been observed to home to the penumbra [13, 23] and recognizing that LG3 is released from parent perlecan DV through the action of focally expressed cathepsin activity [19, 20, 43], we speculate that the administration of 2 mg/kg rhPDV dose to stroke patients may produce an unnecessary delay in neuroprotective action.